Adjunctive techniques to minimize thrombotic complications following microfoam sclerotherapy of saphenous trunks and tributaries

• Published in: Journal of vascular surgery. Venous and lymphatic disorders (New York, NY) NY), 2021-07, Vol.9 (4), p.904-909
• Main Authors: Jimenez, Juan Carlos, Lawrence, Peter F., Woo, Karen, Chun, Tristen T., Farley, Steven M., Rigberg, David A., Baril, Donald T., Derubertis, Brian G.
• Format: Article
• Language: English
• Subjects: Anticoagulants - therapeutic use; Edema; Humans; Patient Positioning; Polidocanol - administration & dosage; Retrospective Studies; Saline Solution, Hypertonic - administration & dosage; Saphenous Vein; Sclerosing Solutions - administration & dosage; Sclerotherapy - adverse effects; Sclerotherapy - methods; Ultrasonography, Doppler, Duplex; Varicose Ulcer - therapy; Varicose veins; Varicose Veins - therapy; Venous insufficiency; Venous Insufficiency - therapy; Venous Thrombosis - diagnostic imaging; Venous Thrombosis - etiology; Venous Thrombosis - prevention & control; Venous ulcer
• ISSN: 2213-333X; 2213-3348
• DOI: 10.1016/j.jvsv.2020.11.015

Thrombus extension into the deep venous system following superficial vein chemical ablation with Varithena polidocanol microfoam has been reported. The objective of this study was to assess the effect of intraoperative improved techniques during treatment for patients with symptomatic varicose veins and their impact on extension of thrombus into deep veins. A retrospective review of a prospectively maintained database was performed. All patients who underwent endovenous chemical ablation with polidocanol microfoam (Varithena, Boston Scientific, Marlborough, Mass) for symptomatic superficial axial and tributary vein reflux were identified. Patients had postoperative duplex (48-72 hours) scanning after the procedure; those who did not adhere to the recommended follow-up were excluded. Demographic data, CEAP Classification, Venous Clinical Severity Score, procedure details, and follow-up data were abstracted. Between April 2018 and August 2020, 157 limbs in 122 patients were treated with Varithena microfoam; 129 limbs in 99 patients met our inclusion criteria. Veins treated included the great saphenous vein (n = 89), anterior accessory saphenous vein (n = 15), small saphenous vein (n = 14), and tributary veins (n = 56). Adjunctive techniques during treatment included intraoperative elevation of the limb to greater than 45°, ultrasound mapping and digital occlusion of large perforator veins, limitation of foam volume per session, injection of sterile saline before treatment, and compression of the limb in the elevated position. The preoperative Venous Clinical Severity Score was 11.4 and decreased after treatment to 9.7. The immediate closure rate was 95% with 81% overall symptomatic relief at last follow-up. The mean follow-up was 113.5 days for the entire cohort; two limbs (1.5%) required postoperative anticoagulation for thrombus extension into the deep venous system (common femoral vein n = 1; popliteal vein n = 1) postoperatively for a mean of 22 days. Both resolved with anticoagulation. One asymptomatic limb developed a femoral vein deep venous thrombosis and one symptomatic late deep venous thrombosis was noted 4 months after the procedure. Postoperative pain and phlebitis were reported in 15.6% and 14.8% of patients, respectively, and all had resolved at last follow-up. No pulmonary emboli were noted and no neurologic or visual adverse events were recorded. Adjunctive techniques during microfoam ablation decreased thrombotic complications in our series